It has been reported that BCI promotes the anti-tumor effect of cisplatin in a patient-derived xenograft (PDX) model [21] and attenuates the inflammatory response in LPS-activated macrophages via ERK1/2 upregulation [38]. Here, MAPK3 is linked to neoplasm.